HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40
Genmab A/S
Genmab A/S GMAB | 0.00 |
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:
GMAB) with a Buy and raises the price target from $38 to $40.
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40
Genmab A/S GMAB | 0.00 |